About BlossomHill Therapeutics
BlossomHill Therapeutics is a private company based in San Diego, California. It has reported $245,802,819 raised in four offerings on Form D since January 2021. Its chief executive is Jingrong Jean Cui.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 25, 2025 | Dec 10, 2025 | $84,152,909fully sold | 47 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Dec 28, 2023 | Jan 2, 2024 | $88,649,917of $99.9M target | 44 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Mar 1, 2021 | Mar 1, 2021 | $70,999,993fully sold | 27 | $2.6M | EquityRule 506(b) | Form D ↗ |
| Dec 31, 2020 | Jan 11, 2021 | $2,000,000fully sold | 3 | $666K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $245,802,819 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on BlossomHill Therapeutics's Form D filed Dec 10, 2025.
GL
George Lee
Director
CG
Carl Gordon
Director
Also a director at ADARx Pharmaceuticals, Avenzo Therapeutics and Garuda Therapeutics.
YL
Yishan Li
Executive officer and director
SA
Sundeep Agrawal
Director
BC
TS
Timothy Stubbs
Director
JC
Jingrong Jean Cui
President and Chief Executive Officer, director
Earlier filings also listed Hongbo Lu (director, last listed Jan 2024).